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Abstract: Oxidative stress plays an important role in the progression of vascular endothelial 
dysfunction. The two major systems generating vascular oxidative stress are the NADPH oxidase 
and the xanthine oxidase pathways. Allopurinol, a xanthine oxidase inhibitor, has been in clini-
cal use for over 40 years in the treatment of chronic gout. Allopurinol has also been shown 
to improve endothelial dysfunction, reduce oxidative stress burden and improve myocardial 
efﬁ  ciency by reducing oxygen consumption in smaller mechanistic studies involving various 
cohorts at risk of cardiovascular events. This article aims to explain the role of xanthine oxidase 
in vascular oxidative stress and to explore the mechanisms by which allopurinol is thought to 
improve vascular and myocardial indices.
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Introduction
The role of oxidative stress in disease has always been a contentious issue because 
attempts to reduce oxidative stress using antioxidant vitamins such as in the Heart 
Outcomes Prevention Evaluation (HOPE) study have consistently failed to demon-
strate a mortality beneﬁ  t.1 There are many possible reasons for this, not least because 
of cohort selection and inappropriate dosing of antioxidants. Even if adequate doses 
were used, at many magnitudes higher than currently taken as part of multivitamin 
supplementation, there would be further issues with tolerability and safety. Therefore, 
recent research has concentrated on mechanisms to reduce the formation of reactive 
oxygen species (ROS) rather than a scavenging approach to already-formed ROS. 
The two major ROS generating systems are the nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase and the xanthine oxidase (XO) systems.
Background
ROS consists of molecular oxygen and all of its aerobic cellular metabolites including 
superoxide (O2
–) and hydroxyl radical (OH–). Other substances such as hydrogen 
peroxide (H2O2), peroxynitrite (ONOO–) and hypochlorous acid (HOCL) have oxidative 
properties although they are not free radicals.2 McCord and Fridovich were one of the 
ﬁ  rst to describe the deleterious effects of ROS in inﬂ  ammation in an article describing 
the enzyme superoxide dismutase.3 Since then, there has been an abundance of research 
demonstrating the role oxidative stress plays in the pathophysiology of abnormal 
vasorelaxation. There is also increasing evidence that oxidative stress plays a direct 
role in myocardial remodeling.4,5 above and beyond its effects on vasomotion.
Enhanced production of reactive oxygen species (ROS) is a major cause of endothe-
lial dysfunction. This has been demonstrated in animal studies using p66SHC knockout 
mice which demonstrate reduced aortic endothelial cell superoxide production and 
a 30% prolonged lifespan.6 The precise role of p66SHC remains unclear but in studies 
looking at its effects on the p53 signaling pathway demonstrate that it is involved Vascular Health and Risk Management 2009:5 266
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in stress-activated p53-induced elevation of intracellular 
oxidants, apoptosis and regulation of the intracellular redox 
state.7 This is consistent with the ﬁ  nding that ROS promotes 
apoptosis and microvascular rarefaction in spontaneously 
hypertensive rats.8 Furthermore, in chronic heart failure 
(CHF) patients with the Glu298Asp variant (Glu to Asp 
amino acid substitution for codon 298 of endothelial nitric 
oxide synthase (eNOS)) have a signiﬁ  cantly shorter eNOS 
half-life. This translates to a signiﬁ  cantly lower event-free 
survival.9 There is also evidence that the same polymorphism 
results in blunting of the endothelial-dependent vasodilation 
in healthy individuals.10
NADPH oxidase catalyzes the reduction of oxygen 
through electron donation from either NADH (predomi-
nantly) or NADPH to generate superoxide (O2
–). This system 
is thought to be the predominant driver of O2
– formation. The 
most potent inducer of the NADPH oxidase system is angio-
tensin II,11,12 and there are angiotensin II antagonists in the 
form of ACE inhibitors, angiotensin II receptor antagonists 
and direct renin inhibitors (DRA) in clinical use. The other 
enzyme system, XO, has been largely ignored with regards 
to managing oxidative stress despite the availability of XO 
inhibitors allopurinol, oxypurinol and febuxostat. This is 
primarily because most of the data for the beneﬁ  cial effect of 
these agents have come from smaller mechanistic studies and 
the lack of large clinical trial evidence to support widespread 
use. The two larger studies using the XO inhibitor oxypurinol 
either showed neutral.13 (in LA-PLATA) or negative results 
(OPT-CHF)14 which may have been due to an insufﬁ  cient 
dose-effect or patient selection. A subsequent follow-up 
study14 found a signiﬁ  cant beneﬁ  t in patients with high 
baseline urate, which could imply either high XO activity 
or that urate itself is detrimental. A recent study in patients 
with type II diabetes suggests that urate lowering per se does 
not improve endothelial function.15
Xanthine oxidase (XO)
Xanthine oxidoreductase (XOR) is part of a group of enzymes 
known as the molybdenum iron-sulfur ﬂ  avin hydroxylases. 
It was ﬁ  rst discovered in milk by Schardinger in 190216 and 
is thought to be involved in reactions that produce ROS 
such as nitrite which enable newborn infants to overcome 
gut-associated bacterial gastroenteritis.17,18 XOR is widely 
distributed throughout various organs including the liver, gut, 
lung, kidney, heart, brain and plasma19 with the highest levels 
being found in the gut and the liver.20 In the myocardium, it is 
localized to the capillary endothelial cells.21 The gene encoding 
for XOR is located at the short arm of chromosome 2.22 It exists 
in two inter-convertible forms known as XO (EC 1.1.3.22) and 
xanthine dehydrogenase (XDH) (EC 1.17.1.4).23 Both enzymes 
consist of two identical subunits of 145 kDa.
Mammalian XOR is present in vivo as the dehydrogenase 
form but is easily converted to XO by oxidation of the sulfhy-
dryl residues or by proteolysis.19 Although XDH has a much 
greater afﬁ  nity for NAD+ compared to oxygen (and therefore 
is practically incapable of directly producing ROS), both XO 
and XDH can oxidize NADH which results in ROS forma-
tion.24 Physiologically, XOR is involved in the hydroxylation 
of purines, pterins, and aldehydes but its primary role is as 
the rate-limiting enzyme in the conversion of hypoxanthine 
to xanthine and xanthine to urate (Figure 1). XOR is the only 
enzyme capable of catalyzing the formation of urate in man.25 
In lower mammals, an enzyme, urate oxidase further metabo-
lizes uric acid to allantoin but this enzyme is inactivated 
in primates.26 There is also a suggestion from teleological 
studies that urate may have even evolved as a compensatory 
mechanism in higher primates that have lost the capacity to 
generate other antioxidants like ascorbate in vivo.27
The mechanism by which XOR catalyzes hypoxanthine 
and xanthine conversion is extremely complex and has 
been previously described in detail.16,28 A fully reduced XO 
contains six electrons and its re-oxidation involves electron 
transfer to oxygen molecules which generates two H2O2 
and two O2
– species28 for every fully reduced XO molecule 
(Figure 1).
There is a large variability in human XOR expression which 
can be up to three-fold and on average 20% higher in men 
than in women.29 Although basal expression of XOR is low 
in humans, hypoxia, IL-1, IL-6, TNF-α, lipo-polysaccharides 
as well as steroid treatment have been shown to upregulate 
transcription.16 XO is signiﬁ  cantly elevated in a variety of 
conditions including limb ischemia,30 major surgery31 coronary 
artery disease (CAD)32 and heart failure.33 Circulating XO binds 
to glycosaminoglycans on the surface of endothelial cells where 
it is thought it acquires modiﬁ  ed kinetics (higher Km and Ki, 
oxidant producing capacity, and increased stability).34 There are 
suggestions that this form of induced, circulating and deposit-
ing XO appears to be more important in the pathogenesis of 
endothelial injury compared with XO constitutively produced 
from endothelial cells.35
Despite this, the activity of endothelial bound XO is 
increased by more than 200% in patients with CHF.36 Fur-
thermore, studies using electron spin resonance have demon-
strated that endothelial oxygen tension is thought to regulate 
XO activity at a post-translational level as demonstrated by a 
doubling in XOR activity post exposure to hypoxia without Vascular Health and Risk Management 2009:5 267
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any increase in mRNA expression for 24 hours in bovine 
aortic endothelial cells.37 Cells produce a marked elevation 
in XO levels when exposed to ischemia38 and XDH conver-
sion to XO is also accelerated in hypoxia.39 When infused 
acutely, XO produces a marked decrease in cardiac contractil-
ity, cardiac index and left ventricular systolic pressure.40 In 
atherosclerotic plaques, urate levels are found to be elevated 
six-fold, reﬂ  ecting accelerated purine oxidation within these 
plaques. Therefore XO production may not necessarily be 
reﬂ  ected by systemic levels of XO metabolites.41
The XO inhibitor allopurinol
Recent evidence indicates that allopurinol improves endo-
thelial dysfunction in high risk primary prevention patients 
such as those with metabolic syndrome.42
Allopurinol has also been shown to normalize endothelial 
dysfunction in type 2 diabetics with mild hypertension and 
reduced plasma malondialdehyde (MDA) levels.43 MDA 
results from acid hydrolysis of lipid peroxides which are 
formed by free radical attack on plasma lipoproteins. It is 
therefore used as an indirect measure of oxidized low-density 
lipoprotein (LDL).
In the experimental murine myocardial infarction model, 
allopurinol signiﬁ  cantly attenuated LV dilatation, hypertrophy, 
ﬁ  brosis and dysfunction. Once again, XO expression (as deter-
mined by electron spin resonance spectroscopy) and myocardial 
ROS generation were markedly increased in the post-mycardial 
infarction ischemic model.44 This suggests a role for allopuri-
nol in LV remodeling, a possibility that we are investigating 
at present in our unit. Allopurinol has also been shown to be 
beneﬁ  cial in conditions such as post coronary artery bypass 
surgery where it reduced ischemic events and produced less 
ST segment depression45 as well as in hypercholesterolemic 
patients.46 There are mixed data from ischemic-reperfusion 
studies. Pacher et al,19 in an excellent in-depth review on this 
topic, have summarized the data in the Table 1.
Allopurinol in CHF was assessed by Doehner et al47 and 
by Farquharson et al.48 Doehner et al showed that the degree 
of improvement in forearm blood ﬂ  ow correlated with the 
degree of urate lowering. Interestingly, they also measured 
allantoin, a marker of oxygen free radical generation, which 
was reduced by 20% following 300 mg/day allopurinol. 
Farquharson et al48 from our unit, found a 181% change in 
forearm blood ﬂ  ow with 300 mg allopurinol. They also found 
a 33% reduction in plasma MDA levels in patients treated 
with 300 mg allopurinol suggesting that the improvement in 
endothelial function and NO bioavailability seen was due (at 
least in part) to a reduction of ROS generation or oxidative 
stress burden. Allopurinol also reduced B-type natriuretic 
peptide (BNP) in stable CHF patients, although the reduction 
did not correlate with the fall in urate.49
We have shown previously that high dose allopurinol 
is a very effective antioxidant in the vasculature because it 
abolishes the vitamin C-sensitive component of oxidative 
stress on vascular endothelial function, ie, in patients on 
high dose allopurinol, there is insufﬁ  cient vascular oxidative 
stress being formed for vitamin C to neutralize the oxidative 
stress and further improve endothelial function.50 This is 
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Figure 1 The purine degradation pathway. Reproduced with permission from Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms 
and pathophysiological implications.  J Physiol. 2004; 555(Pt 3):589–606.16 Copyright © Blackwell Publishing.Vascular Health and Risk Management 2009:5 268
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further strengthened by evidence that the beneﬁ  cial effect 
of vitamin C co-infusion in patients with CHF was great-
est in patients with the highest levels of oxidative stress as 
measured by extracellular superoxide dismutase (ecSOD)36 
and XO activity.
Interestingly, it is the ability of allopurinol to inhibit XO, 
and therefore ROS, that results in its inclusion as a constituent 
in the University of Wisconsin solution for organ transport 
prior to transplantation.51
The biomarker of lipid peroxidation, F2-isoprostane, is 
an indirect but validated marker of oxidative stress. Data 
from our group (unpublished) also demonstrate the ability 
of allopurinol to signiﬁ  cantly reduce F2-isoprostane levels 
in patients with high baseline oxidative stress, further 
conﬁ  rming the potent antioxidant effect of allopurinol. This 
also reﬂ  ects XO activity within the vascular milieu in these 
patients because for the same degree of urate lowering as 
those with low baseline oxidative stress, only patients with 
high pre-existing oxidative stress were found to have a 
signiﬁ  cant reduction in F2-isoprostanes. This is consistent 
with the known cascade effect of multiple superoxide and 
hydrogen peroxide generation for every urate molecule for-
mation that is catalyzed by XO.16,62 In fact, NO and O2
– react 
at a three-fold greater rate than the rate at which antioxidant 
defense mechanisms such as SOD can eliminate O2
–.63
In chronic diseases such as CHF, sustained high levels 
of ROS may exceed the capacity of cellular enzymatic and 
non-enzymatic antioxidants64 to counter its effects. Using 
electron spin resonance, Spiekermann et al demonstrated that 
both NADPH oxidase and xanthine oxidase are up-regulated 
in patients with coronary artery disease.32 Others have dem-
onstrated increased levels in CHF.36,65
Direct antioxidant action 
of allopurinol
Allopurinol directly scavenges free radicals as demonstrated 
by Das et al and others66–68 in in vitro hearts where evidence 
of free radical scavenging occurred in the absence of XO 
activity. Animal studies in experimentally induced uveitis 
show that at very high doses (up to 50 mg/kg), allopurinol 
behaves as a free radical scavenger with intrinsic antioxidant 
properties. Crucially, this was only achieved far beyond the 
XO inhibition dose of 10 mg/kg and not at that dose itself. 
Further evidence for a possible direct antioxidant effect of 
allopurinol comes from models of experimental colitis where 
tungsten (a potent XO inhibitor) failed to improve symptoms 
whereas allopurinol did.69 Augustin et al suggested that this 
direct effect was only seen at higher doses.70 This was also 
seen in mice paracetamol toxicity models where lower doses 
(sufﬁ  cient to block XO activity) of allopurinol failed to show 
antioxidant protection but higher doses did.71 There have 
been other non-XO effects of allopurinol suggested such as 
copper chelation, preventing LDL oxidation as described 
above,72 inhibition of heat shock protein (hsp) expression73 and 
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Figure 2 Mechanism of xanthine oxidoreductase XOR reaction with xanthine;   A) reductive half reaction; B) oxidative half reaction. Reproduced with permission from 
Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications.   J Physiol. 2004; 555(Pt 3):589–606.16 
Copyright © Blackwell Publishing.Vascular Health and Risk Management 2009:5 269
Allopurinol in vascular oxidative stress
Table 1 Effects of xanthine oxidase (XO) inhibitors in myocardial ischemia-reperfusion injury
Model Disease or trigger Mode of XO 
inhibition
Effects of XO 
inhibition
Reference
Human (169 patients) Coronary bypass 
surgery
Allopurinol Decreased hospital mortality 
rate, increased cardiac index
Johnson et al52
Human (90 patients) Coronary bypass 
surgery
Allopurinol Reduced arrhythmias, need 
for inotropes and perioperative 
myocardial infarction in patients
Rashid and William-Olsson53
Human (140 patients) Myocardial I Allopurinol Increased incidence of infarct 
extensions in the treatment 
group
Parmley et ala54
Human (80 patients) Ischemic heart 
disease
Allopurinol + erinit Decreases in serum and daily 
urinary levels of uric acid and 
lipid peroxidation antioxidative 
system and an improvement 
of central hemodynamics
Kaliakin and Mit'kin55
Human (50 patients) Coronary bypass 
surgery
Allopurinol Improves postoperative 
recovery and reduces lipid 
peroxidation in patients 
undergoing coronary artery 
bypass grafting
Coghlan et al56
Human (20 patients) Coronary bypass 
surgery
Allopurinol Failed to demonstrate a 
cardioprotective effect of 
allopurinol in patients with 
good left ventricular function 
undergoing elective coronary 
artery surgery
Taggart et ala57
Human (20 patients) Coronary bypass 
surgery
Allopurinol Allopurinol suppressed the 
reaction rate of XO; therefore, 
the levels of intermediates, 
hypoxanthine and xanthine, 
were high, and the level of the 
ﬁ  nal product, uric acid, was low 
– however, allopurinol had no 
efﬁ  cacy for the level of lactate, 
pyruvate, CK, and CK-MB
Yamazaki et ala58
Human (33 patients) Coronary bypass 
surgery
Allopurinol Better recovery of cardiac 
output and left ventricular 
stroke work after bypass 
surgery and reduction of plasma 
XO activity and concentrations 
of uric acid
Castelli et al59
Human (52 patients) Coronary bypass 
surgery
Allopurinol Allopurinol failed to improve 
left ventricular stroke work 
after cardiopulmonary bypass 
surgery
Coetzee et ala60
Human (38 patients) Percutaneous 
transluminal coronary 
angioplasty in patients 
with acute myocardial 
infarction
Allopurinol Allopurinol pretreatment was 
effective in inhibiting generation 
of oxygen-derived radicals 
during reperfusion and in 
the recovery of left ventricular 
function
Guan et al61
Adapted with permission from Pacher P,  Nivorozhkin A, Szabo C.   Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. 
Pharmacol Rev. 2006; 58(1):87–114.19 Copyright © 2006 American Society for Pharmacology and Experimental Therapeutics.
aStudies concluded with negative results.
Abbreviations: I/R, ischemia-reperfusion; I, ischemia; CK, creatine kinase.Vascular Health and Risk Management 2009:5 270
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calcium sensitization (below). Allopurinol treatment reduces 
early changes in inﬂ  ammation such as leukocyte activation 
by reducing adherence, rolling and extravasation.74
Mechanoenergetic uncoupling
This phenomenon refers to an imbalance between left ven-
tricular performance and myocardial energy consumption.75 
The role of XO inhibition may either be to maintain cardiac 
output while reducing myocardial oxygen consumption or 
even increase cardiac output without increasing myocardial 
oxygen consumption. In dogs with pacing-induced heart 
failure, allopurinol improved myocardial contractility and 
eff  iciency in oxygen utilization, prevented increases in 
systemic vasoconstriction and ameliorated reductions in 
myocardial contractility.65,76,77 In murine post-ischemic car-
diomyopathy models, allopurinol attenuated the increase in 
end-systolic and end-diastolic volumes,78 increased survival, 
augmented ventricular function as well as reduced products of 
lipid peroxidation.79 Khan et al found a direct protein-protein 
interaction between XO and neuronal NOS in the sarcoplas-
mic reticulum of cardiac myocytes.80 Allopurinol improved 
myoﬁ  lament calcium sensitivity as contraction force increased 
without a concomitant rise in systolic Ca2+ inﬂ  ux. The effects 
were not seen in endothelial NOS deﬁ  cient mice, suggesting 
a role for neuronal NOS preventing XO inhibition of cardiac 
excitation-contraction coupling.80 The ﬁ  nding that allopurinol 
is a potent myoﬁ  lament Ca2+ sensitizer, particularly in the set-
ting of ischemia, is thought to be due to the inhibition of basal 
XO production. As with the previous study by Khan et al, Perez 
et al found an almost exclusive increase in force generation 
without a lowering of inward transient Ca2+.81
Despite the small sample size (n = 9), Cappola et al 
showed using cardiac catheterization that direct intra-
coronary infusions of allopurinol in these patients resulted 
in a marked decrease in myocardial oxygen consumption 
(MVO2) with no decrease in the rate of left ventricular pres-
sure rise (dP/dT), stroke work or ventricular load.82 Patients 
post coronary artery bypass grafting given allopurinol have 
also been shown to require less inotropic support.45
Conclusion
The evidence for the role of oxidative stress in disease cannot 
be disputed. However, there are many questions that remain 
such as (1) exactly what is the contribution of oxidative stress 
to overall endothelial dysfunction; (2) at what stage should 
intervention take place; (3) what agents can we employ to 
effectively deal with this ubiquitous problem, which will be 
both safe and tolerable to our patients? The emerging evidence 
from therapies such as allopurinol are encouraging and should 
be put to the test in larger randomized studies to determine if 
the interesting data garnered from smaller mechanistic studies 
actually translate to a survival advantage with these agents.
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